Navann Ty

Stock Analyst at Exane BNP Paribas

(3.21)
# 2,477
Out of 4,531 analysts
39
Total ratings
55.6%
Success rate
7.1%
Average return

Stocks Rated by Navann Ty

Organon & Co.
Apr 28, 2026
Downgraded: Hold
Price Target: $15$14
Current: $13.52
Upside: +3.55%
Medline
Jan 12, 2026
Initiated Coverage: Hold
Price Target: $38
Current: $39.79
Upside: -4.50%
Natera
Oct 27, 2025
Upgraded: Hold
Price Target: $28$172
Current: $271.39
Upside: -36.62%
GE HealthCare Technologies
Sep 10, 2025
Reiterated: Buy
Price Target: $92
Current: $63.07
Upside: +45.87%
Phibro Animal Health
Sep 4, 2025
Maintained: Hold
Price Target: $24$37
Current: $33.31
Upside: +11.08%
The Cooper Companies
Jul 22, 2025
Upgraded: Buy
Price Target: $92
Current: $71.71
Upside: +28.29%
Kenvue
May 30, 2023
Initiated Coverage: Hold
Price Target: $28
Current: $18.98
Upside: n/a
SkinHealth Systems
Mar 20, 2023
Upgraded: Hold
Price Target: n/a
Current: $0.8438
Upside: n/a
AbbVie
Dec 8, 2022
Initiated Coverage: Hold
Price Target: $169
Current: $254.49
Upside: n/a
Evolus
Dec 8, 2022
Initiated Coverage: Buy
Price Target: $13
Current: $5.73
Upside: n/a
Maintained: Hold
Price Target: $22$26
Current: $52.72
Upside: n/a
Maintained: Hold
Price Target: $16$11
Current: $17.29
Upside: n/a
Maintained: Hold
Price Target: $232$208
Current: $76.56
Upside: n/a
Initiated Coverage: Buy
Price Target: $200
Current: $247.53
Upside: n/a
Maintained: Buy
Price Target: $39$42
Current: $25.83
Upside: n/a
Maintained: Buy
Price Target: $36.42$51.83
Current: $6.78
Upside: n/a
Initiated Coverage: Hold
Price Target: $10
Current: $32.03
Upside: n/a